摘要
目的探讨硝苯地平联合泮托拉唑治疗肝硬化合并食管胃静脉曲张破裂出血(EGVB)患者的临床疗效,以及联合治疗对于血清血管紧张素转化酶(ACE)、一氧化氮(NO),胃肠激素及肝功能的影响。方法选择2014年10月至2017年10月在陕西省核工业二一五医院就诊的91例肝硬化合并EGVB患者,按随机数字表法分为44例对照组和47例研究组。对照组给予泮托拉唑治疗,研究组在对照组基础上联合硝苯地平治疗。比较两组患者的临床疗效,止血时间,再出血率,住院时间,血清ACE、NO表达水平,胃肠激素表达水平,肝功能,以及不良反应发生情况。结果研究组的总有效率高于对照组,且止血时间、再出血率及住院时间均低于对照组,差异均有统计学意义(P均<0.05)。治疗后,两组患者的血清ACE、NO及胃肠激素表达水平均下降,且研究组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者的总胆红素(TBiL)、丙氨酸氨基转移酶(ALT)表达下降,白蛋白(Alb)表达升高,且研究组的变化程度更显著(P<0.05)。两组患者的不良反应发生率差异无统计学意义(P>0.05)。结论硝苯地平联合泮托拉唑治疗肝硬化合并EGVB患者的临床疗效确切,能够降低血清ACE及NO表达水平,调节胃肠激素分泌,改善肝功能。
Objective This paper is to investigate the clinical efficacy of nifedipine combined with pantoprazole in the treatment of patients with cirrhosis and esophageal varices bleeding (EGVB), and the effect of combined treatment on serum angiotensin converting enzyme (ACE), nitric oxide (NO), gastrointestinal hormones and liver function. Methods Ninety-one patients with cirrhosis and EGVB who were treated from October 2014 to October 2017 in the No. 215 Hospital, Nuclear Industry of Shaanxi Province were randomly divided into the control group and the research group, with respectively 44 and 47 cases in each group. The control group was treated with pantoprazole while the research group with nifedipine, apart from pantoprazole. The clinical efficacy, hemostasis time, rebleeding rate and hospitalization time, serum levels of ACE, NO, gastrointestinal hormone, liver function and adverse reactions in both groups were compared. Results The total effective rate of the research group was higher than that of the control group. The hemostasis time, rebleeding rate and hospitalization time of the research group were lower than those of the control group, with statistically significant differences( P < 0.05). After treatment, although the expression levels of serum ACE, NO and gastrointestinal hormones of the two groups were decreased, the expression levels of serum ACE, NO, and gastrointestinal hormones of the research group were lower than those of the control group, with a statistically significant difference( P <0.05);although the expression of total bilirubin (TBiL), alanine aminotransferase (ALT) decreased and the expression of albumin (Alb) were increased in both groups, the levels of change in the research group were more significant ( P <0.05). However, there was no statistically significant difference in the incidence of adverse reactions between the two groups ( P > 0.05 ). Conclusion Nifedipine combined with pantoprazole has a definite clinical effect on the treatment of cirrhosis patients with EGVB, which can reduce
作者
王景景
张洋
郭倩
田妍
吕婷
夏军龙
WANG Jingjing;ZHANG Yang;GUO Qian;TIAN Yan;LYU Ting;XIA Junlong(Department of Pharmacy,No.215 Hospital,Nuclear Industry of Shaanxi,Xianyang 712000,China;Department of Gastroenterology,No.215 Hospital,Nuclear Industry of Shaanxi Province,Xianyang 712000,China)
出处
《国际消化病杂志》
CAS
2019年第1期30-35,共6页
International Journal of Digestive Diseases
基金
陕西省自然科学基础研究计划项目(2017JM8163)
